Quaker Chemical Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw the election of three directors, approval of executive compensation, and ratification of PwC as auditor. The Chair announced his retirement, highlighting the CEO's strategic initiatives for future growth. No shareholder questions were raised.
-
Organic volumes and net sales grew year-over-year, led by Asia Pacific and new business wins, despite soft end markets and inflationary pressures. Gross margins improved, but Q2 will see temporary margin compression due to higher input costs, with recovery expected by year-end.
Fiscal Year 2025
-
Q4 and full-year results showed strong EBITDA and EPS growth, driven by Asia-Pacific momentum and share gains despite soft Americas and EMEA markets. Cost actions, acquisitions, and network optimization support improved margins and outlook for continued growth in 2026.
-
Third quarter saw 7% sales growth and 10% adjusted EPS growth year-over-year, led by strong Asia-Pacific performance and new business wins. Cost controls, Dipsol integration, and capital discipline supported margin and cash flow improvements, with continued growth expected in Q4.
-
Q2 2025 saw 4% sales growth and 2% organic volume growth, led by Asia Pacific and advanced solutions. Adjusted EBITDA margin was 15.6%, with strong cash flow and disciplined cost actions. Market softness is expected to persist, but above-market growth and improved earnings are forecast for H2 2025.
-
First quarter 2025 results were in line with expectations, with net sales down 6% year-over-year and adjusted EBITDA of $69 million. Market share gains, cost actions, and three acquisitions, including DIPSOL, are expected to support stable full-year results despite ongoing tariff and demand uncertainty.
-
A global leader in industrial process fluids, the company is focused on growth, operational simplification, and disciplined capital allocation under new leadership. Margin recovery, targeted M&A, and a balanced end-market mix support resilience amid industry and macro challenges.
Fiscal Year 2024
-
Q4 net sales declined 5% year-over-year, but stable volumes and strong cash flow enabled continued investment, M&A, and shareholder returns. 2025 guidance calls for revenue, EBITDA, and earnings growth, with gross margins stable and cost actions supporting profitability.
-
Q3 2024 saw stable sales and strong margins despite a 6% year-over-year revenue decline, with robust performance in Asia-Pacific offsetting softness in Americas and EMEA. Cost discipline, new business wins, and strategic acquisitions supported resilient earnings and cash flow.
-
Q2 saw margin expansion and earnings growth despite a 6% sales decline, with strong Asia Pacific performance and stable volumes amid soft end markets. Guidance calls for modest sequential demand improvement and continued earnings growth, supported by disciplined capital allocation and recent acquisitions.